A randomized, open-label, multicenter, dose escalation study of HQK-1001 (2,2-dimethylbutyrate, sodium salt) in sickle cell disease

Authors
Category Primary study
JournalBlood
Year 2012
This article has no abstract
Epistemonikos ID: 7e7ab935a1f57d8c81f5fe0bb6189d856f6e8c0f
First added on: Feb 05, 2025